 | Up a level |
Salwender, Hans, Bertsch, Uta, Weisel, Katja, Duerig, Jan, Kunz, Christina, Benner, Axel, Blau, Igor W., Raab, Marc Steffen, Hillengass, Jens, Hose, Dirk, Huhn, Stefanie, Hundemer, Michael, Andrulis, Mindaugas, Jauch, Anna, Seidel-Glaetzer, Andrea, Lindemann, Hans-Walter, Hensel, Manfred, Fronhoffs, Stefan, Martens, Uwe, Hansen, Timon, Wattad, Mohammed, Graeven, Ullrich, Munder, Markus, Fenk, Roland, Haenel, Mathias, Scheid, Christof and Goldschmidt, Hartmut (2019). Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer, 19. LONDON: BMC. ISSN 1471-2407
Vehreschild, Maria J. G. T., Meissner, Arne M. K., Cornely, Oliver Andreas, Maschmeyer, Georg, Neumann, Silke, von Lilienfeld-Toal, Marie, Karthaus, Meinholf, Wattad, Mohammed, Staib, Peter, Hellmich, Martin 
ORCID: 0000-0001-5174-928X, Christ, Hildegard ORCID: 0000-0003-3235-2994 and Vehreschild, Joerg Janne
(2011).
Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients.
Haematol-Hematol. J., 96 (12).
S. 1855 - 1861.
PAVIA:
FERRATA STORTI FOUNDATION.
ISSN 0390-6078